Investor

Active Biotech is developing pharmaceutical products within medical areas where the immune defense is of significant importance like inflammatory disease and various forms of cancer.

Active Biotech’s share is listed on the NASDAQ OMX Nordic Exchange (Stockholm) since 1986 and the company has approximately 14,500 shareholders.

Short Name
ACTI

Press Releases

Financial Reports

Latest Presentation

Redeye video interview with CEO Helén Tuvesson (in Swedish)

Events and Financial Calendar

Date: May 22, 2024
Date: August 22, 2024

Helén Tuvesson

IR Contact

Phone: +46 46 19 21 56

E-mail: helen.tuvesson@activebiotech.com

Hans Kolam

IR Contact

Phone: +46 46 19 20 44

E-mail: hans.kolam@activebiotech.com